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The SF-36 was converted into a utility using the preference-based SF-6D. Clinical 
outcomes such European League Against Arthritis (EULAR) Disease Activity Score 
(DAS), joint counts and laboratory measures were also recorded. We calculated single 
index utility scores from the preference-based instruments using UK population norms. 
We used regression analysis and correlation coefﬁcients to compare relationships 
between the Quality of Life (QoL) outcomes and also the clinical outcomes and 
between observed and mapped utility scores. RESULTS: There was a signiﬁcant dif-
ference between the mapped and observed EQ-5D and SF-6D. Overall the mapped 
utilities produced higher values than the actual observed scores. The mean change in 
utility due to treatment is greater with the EQ-5D for both mapped and observed 
utilities. A greater change was seen in the PsA group. CONCLUSIONS: We present 
the different results produced when using mapped utility scores and directly obtained 
scores. We have highlighted the problems associated with deriving utilities from non 
preference-based instruments and the differences in utilities when calculated using 
different measures. While these methods do offer alternatives for researchers when 
performing cost utility analysis they remain suboptimal to the direct method.
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OBJECTIVES: To test the comprehension of the FMBA© in France, Germany and 
Spain. METHODS: The FMBA© was tested to assess ease of comprehension, cultural 
equivalence, clarity, wording and acceptability of the structure and content to patients. 
The test version contained 79 items grouped into 7 sections measuring burden of 
ﬁbromyalgia on patients’ daily lives, developed simultaneously in French, German, 
Spanish and UK English. These sections evaluate Pain, Physical Impact, Impact on 
daily activities, Social Impact, Work Impact, Psychological Impact, Relationship to 
doctors and treatment, and One general item. Sixteen ﬁbromyalgia patients were 
interviewed in France, Germany and Spain. UK comprehension tests are currently 
under way. Based on test results and deliberation with ﬁbromyalgia experts, changes 
were made to the French, German, Spanish and UK English versions of the question-
naire during an international harmonisation meeting. RESULTS: Patients’ overall 
comprehension of the questionnaire was good. The comprehension tests identiﬁed 
problematic items, and suggestions for deletions or rewording. Seventeen items were 
deleted for reasons such as; lack of conceptual clarity e.g. “I have pain that changes 
from one moment to the next” not clear between location and intensity; items con-
sidered conceptually too close e.g. “I get tired for no reason” deleted because too close 
to “I lack energy” and “I get tired easily”; and wording too strong” e.g. “I feel handi-
capped”. The answer choices were also modiﬁed to ensure cultural acceptance. The 
pilot version of the FMBA© contains 62 items divided into 7 sections. CONCLU-
SIONS: The FMBA© is a questionnaire that assesses the functional impact and burden 
of ﬁbromyalgia on patients’ daily lives. The FMBA© will allow the consequences of 
FM on patients to be more widely recognised. A validation study is to be undertaken 
to validate psychometric properties and scoring of the questionnaire.
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OBJECTIVES: To develop a European screening tool to help primary care physicians 
(PCPs) identify ﬁbromyalgia (FM) patients in general practice. METHODS: A Euro-
pean multidisciplinary expert group was set up to provide clinical expertise and iden-
tify key issues around FM detection. A literature review and focus groups conducted 
with French (FR), German (DE) and English (UK) clinicians provided an overview of 
the knowledge in FM and of clinicians’ awareness and experience. Psychologists then 
performed face-to-face exploratory interviews with FM patients (FR, DE and UK, n 
 29) to understand their attitudes and perceptions of the disease. Based on the ﬁnd-
ings, items were simultaneously generated in FR, UK and DE. The resulting tool was 
comprehension tested with FM-diagnosed or -suspected patients (n  3 and n  2 in 
each country, respectively), and modiﬁed based on results. Its acceptability and appli-
cability was then assessed in real-life conditions in general practice. RESULTS: The 
tool content deﬁned using literature review, health professional and patient input had 
high consistency regardless of the source from which it was extracted. Factors found 
that may contribute to the early detection of FM included elements of FM deﬁnition, 
patient characteristics, personal and medical history, quality of life, attitude and per-
sonality, associated symptoms and inﬂuencing factors. The resulting pilot version of 
the FM screening tool includes 14 questions assessing patients’ pain, fatigue, associ-
ated symptoms, impact on patients’ everyday life, personal history, and attitudes 
towards their symptoms. Face validity and feasibility have been conﬁrmed by PCPs 
and patients when administered in general practice. CONCLUSIONS: In addition to 
the symptomatic picture, FM detection requires the assessment of multiple factors 
including patient past history and characteristics, impact of FM on patients’ daily life, 
and situations/factors affecting patients’ condition. By capturing each of these factors, 
the European FM screening tool will help PCPs identify potential FM patients. Quan-
titative validation of the tool is underway.
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OBJECTIVES: Health related quality of life (HRQoL) is an important issue to evaluate 
outcomes after health interventions. The aim of this study was to study construct 
validity and responsiveness of the OsteoArthritis of Hip and Knee Quality of Life 
questionnaire (OAKHQOL), a disease-speciﬁc HRQoL for osteoarthritis of the lower 
limb. METHODS: OAKHQOL is a self administered questionnaire and has 43 items 
and ﬁve dimensions: physical activities (16), pain (4), mental health (13), social 
support (4) and social functioning (3). There are 3 independent items about relation-
ships, sexual activities and professional life. The score range from 0 (worst) to 100 
(best health). Patients were recruited patients from the waiting list to undergo joint 
replacement. The internal consistency was measured by Cronbach´s alpha (771 
patients). The test-retest reliability (413 stable patients who fulﬁlled the questionnaire 
two times) was measured by Intraclass correlation coefﬁcient (ICC). The responsive-
ness was evaluated by means of standardized effect size (SES) and standardized 
response mean (SRM) six months post surgical replacement. RESULTS: Cronbach´s 
alpha were all higher than 0.8 but in social activities dimension (0.64). Regarding 
test-retest reliability the ICCs were higher than 0.75 but in the social activities (0.4) 
and social support (0.4) dimensions. Finally, responsiveness parameters were: physical 
dimension (SES  1.26; SRM  0.89); pain (SES  1.37; SRM  0.94); mental health 
(SES  0.65; SRM  0.56). CONCLUSIONS: These results support the validity and 
responsiveness of the Spanish version of the OAKHQOL a disease speciﬁc HRQoL 
questionnaire to be used in patients with osteoarthritis of the lower limb and surgical 
management.
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OBJECTIVES: Development of validated patient-reported outcome (PRO) measures 
has the potential to positively impact scientiﬁc research and patient management. To 
date, the speciﬁc issues and symptoms most relevant to DM1 patients’ health related 
quality-of-life (HRQOL) have not been systematically assessed. Our goal is to identify 
those aspects of HRQOL that are most important to patients with DM1, a neuromus-
cular condition with multisystemic organ dysfunction. METHODS: We conducted 
in-depth individual patient interviews with twenty genetically conﬁrmed, adult, DM1 
patients representing varied levels of disability. Each interview focused on identifying 
the DM1 issues that have the greatest impact on patient HRQOL. Each interview was 
recorded, transcribed, coded, and analyzed using a qualitative framework technique, 
triangulation, and three investigator consensus approach. RESULTS: A total of 1175 
direct quotes were coded resulting in 223 like themes. These themes were subsequently 
categorized into 7 subdomains representing physical, mental, and social aspects of 
DM1 HRQOL. A disease-speciﬁc HRQOL conceptual model was created for DM1 
representing the most relevant symptomatic and psychosocial issues in this population. 
Categories in this model included: 1) mobility and ambulation/ ﬁne motor and upper 
extremity dysfunction; 2) emotional distress; 3) cognitive impairment; 4) social role 
limitations; 5) social role dissatisfaction; 6) activity impairment; and, 7) DM1-speciﬁc 
symptoms of: sleep disturbance, fatigue, pain/myotonia, gastrointestinal dysfunction, 
central sensory impairment, and communication difﬁculties. Difﬁculty with ambula-
tion was the most frequently mentioned issue by our sample of patients. CONCLU-
SIONS: There are multiple themes and symptoms, some previously underrecognized, 
that play a key role in DM1 patient reported HRQOL. These issues must be carefully 
examined in order to develop a representative disease-speciﬁc conceptual model and 
PRO measurement tool. The development of such an instrument has the potential to 
improve DM1 clinical care and maximize the impact and relevance of future DM1 
clinical research.
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OBJECTIVES: The Rheumatoid Arthritis Quality of Life scale (RAQoL) is the ﬁrst 
true QoL measure for RA and is widely used in clinical practice and trials. The scale 
has good psychometric properties and has been shown to be responsive to changes in 
disease severity. The objective of the study was to adapt the RAQoL for USA, Mexico, 
